Brain monitoring co takes $3.5m in series B
This article was originally published in Clinica
Executive Summary
Orasi Medical, a spin-out from the University of Minnesota, has raised $3.5m in series B financing. The funds, which came from un-named investors, will enable the firm to expand the development of its brain function monitoring technology into the pharmaceutical and clinical markets. Pharmaceutical companies will be able to use the test, which Orasi describes as a "quick and patient-friendly" way to monitor electrical brain activity, to assess the effects of drugs for treating neurological disorders.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.